Numinus Wellness Inc. (NUMIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Numinus Wellness Inc. (NUMIF) trades at $0.04 with AI Score 38/100 (Grade D). Numinus Wellness Inc. pioneers psychedelic-assisted psychotherapy through its Numinus Health clinics and supports the industry via Salvation Botanicals' lab services. Market cap: $12.18M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for NUMIF: NUMIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NUMIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NUMIF: 1/1 perspectives are bearish.
How is this calculated? →Numinus Wellness Inc. (NUMIF) Healthcare & Pipeline Overview
Numinus Wellness Inc. is a Canadian healthcare company pioneering psychedelic-assisted psychotherapy through its Numinus Health clinics and supporting research via Salvation Botanicals lab services. It focuses on mental health treatment and substance abuse, positioning itself at the forefront of an emerging therapeutic field while navigating complex regulatory environments and developing specialized expertise.
What Is the Investment Thesis for NUMIF?
Numinus Wellness Inc. operates at the intersection of mental healthcare innovation and emerging psychedelic therapies, presenting a thesis centered on its dual-pronged approach. The company's Numinus Health clinics are positioned to capitalize on the growing demand for alternative mental health treatments, particularly as regulatory acceptance for psychedelic-assisted psychotherapy expands. Concurrently, Salvation Botanicals provides essential laboratory and R&D services, creating a diversified revenue stream that supports the broader psychedelic and cannabis industries. Despite a challenging financial profile, evidenced by a profit margin of -297.9% and a market capitalization of $12.18M, the company's gross margin of 41.5% indicates some operational efficiency within its service delivery. Key growth catalysts include the ongoing expansion of its clinic network, advancements in research protocols for psychedelic treatments, and the potential for favorable regulatory shifts in North America. The high beta of 2.62 reflects significant market sensitivity, typical for an early-stage company in a nascent industry. Investors are evaluating Numinus's ability to scale its operations, secure additional funding, and navigate the complex regulatory and public perception landscape to achieve long-term profitability within this high-growth, high-risk sector.
Based on FMP financials and quantitative analysis
NUMIF Key Highlights
- Market Capitalization: $0.01 billion, reflecting its status as an early-stage company in a developing market.
- Profit Margin: -297.9%, indicating significant current unprofitability as the company invests in growth and research.
- Gross Margin: 41.5%, demonstrating a degree of operational efficiency in its service delivery and lab operations.
- Beta: 2.62, suggesting high volatility and sensitivity to broader market movements, typical for emerging growth companies.
- Employee Count: 200 employees, supporting its dual operations in clinical services and laboratory research and development.
Who Are NUMIF's Competitors?
NUMIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NUMIF's Key Strengths?
- Dual business model integrating clinical services (Numinus Health) with laboratory and R&D capabilities (Salvation Botanicals).
- Early mover advantage in the emerging and high-growth sector of psychedelic-assisted psychotherapy.
- Comprehensive service offerings including therapy, counselling, neurofeedback, and specialized lab testing for psychedelics and cannabis.
- Focus on practitioner training, contributing to the development of a skilled workforce in the field.
What Are NUMIF's Weaknesses?
- Significant unprofitability, indicated by a -297.9% profit margin, posing challenges for sustained operations.
- OTC Other market listing, which typically implies lower liquidity, less stringent disclosure requirements, and higher investor risk.
- High beta of 2.62, suggesting substantial stock price volatility and sensitivity to market fluctuations.
- Reliance on a nascent industry with evolving regulatory frameworks and potential public perception hurdles.
What Could Drive NUMIF Stock Higher?
- Potential for new regulatory approvals or expanded legal frameworks for psychedelic-assisted therapies in key jurisdictions.
- Continued expansion of Numinus Health clinics and service offerings, increasing patient access and market penetration.
- Advancements in clinical research and development of new therapeutic protocols for various mental health conditions.
- Announcement of strategic partnerships or collaborations that could provide capital, expand reach, or enhance R&D capabilities.
- Growth in demand for Salvation Botanicals' specialized lab testing services from the maturing psychedelic and cannabis industries.
What Are the Key Risks for NUMIF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Adverse regulatory changes or delays in the approval and legalization of psychedelic substances for medical use.
- Significant unprofitability (Profit Margin: -297.9%) requiring sustained capital raises and posing going concern risks.
- Intense competition from other companies entering the psychedelic therapy space, including larger pharmaceutical firms.
- Challenges related to its OTC Other listing, including low liquidity, limited disclosure, and potential difficulty in raising capital.
- Public perception risks and potential stigma associated with psychedelic treatments, impacting patient adoption and policy.
What Are the Growth Opportunities for NUMIF?
- **Expansion of Numinus Health Clinic Network:** Numinus Wellness Inc. has a significant growth opportunity in expanding its Numinus Health clinic network across North America and potentially internationally. The demand for effective mental health treatments, particularly for conditions like PTSD, depression, and anxiety, is substantial, with the global mental health market valued in the hundreds of billions. As regulatory bodies continue to approve psychedelic-assisted therapies, Numinus can strategically open new clinics or acquire existing facilities, increasing patient access and revenue streams. This expansion would leverage its established protocols and practitioner training programs, targeting urban centers and underserved regions where mental health services are critical. The timeline for this growth is ongoing, contingent on regulatory progress and capital availability.
- **Increased Demand for Salvation Botanicals' Lab Services:** The Salvation Botanicals division is poised for growth as the psychedelic and cannabis industries mature. As more companies enter these markets, the need for specialized cultivation, analytical testing, and product research and development services will escalate. The global cannabis testing market alone is projected to reach billions, and a similar trajectory is anticipated for psychedelic testing as research and commercialization efforts intensify. Numinus can expand its client base by offering full-suite and bespoke testing, R&D support, and quality assurance for new psychedelic compounds and cannabis products. This opportunity is ongoing, driven by industry growth and regulatory requirements for product safety and efficacy.
- **Advancements in Psychedelic Research and Protocol Development:** Numinus Wellness Inc. can drive growth through its active involvement in psychedelic research and the development of new therapeutic protocols. As clinical trials yield positive results and new compounds are identified, the company can be an early adopter or developer of these treatments. The market for novel mental health therapeutics is vast, with significant unmet needs. By investing in or partnering on research, Numinus can enhance its service offerings, attract more patients, and potentially license proprietary protocols. This positions the company at the cutting edge of treatment innovation, with a long-term timeline for impact as research progresses and new therapies gain regulatory approval.
- **Favorable Regulatory Shifts and Legalization:** The ongoing global trend towards the decriminalization and medical legalization of psychedelics presents a substantial growth opportunity. As more jurisdictions approve substances like psilocybin and MDMA for therapeutic use, the addressable market for Numinus Health's services will expand significantly. This includes potential for broader insurance coverage and reduced operational hurdles. The timeline for these regulatory shifts is variable but generally moving towards greater acceptance, creating a more permissive environment for psychedelic-assisted therapy. Numinus, as an early mover, is well-positioned to capitalize on these changes, potentially leading to rapid scaling of its clinical operations and increased patient volume.
- **Strategic Partnerships and Collaborations:** Forming strategic partnerships with academic institutions, pharmaceutical companies, and other healthcare providers represents a key growth avenue. Collaborations can facilitate joint research, expand geographic reach, and integrate Numinus's services into broader healthcare ecosystems. For instance, partnering with research universities could accelerate protocol development, while alliances with established healthcare networks could provide access to larger patient populations and referral systems. The global market for mental health partnerships is dynamic, offering numerous opportunities for synergistic growth. These partnerships can provide access to capital, expertise, and market penetration, with an ongoing timeline for development as the company seeks to strengthen its market position and capabilities.
What Opportunities Does NUMIF Have?
- Increasing acceptance and legalization of psychedelic therapies for mental health conditions globally.
- Expansion of its clinic network and service offerings to meet growing demand for alternative mental health treatments.
- Growth in the demand for specialized lab testing and R&D services within the psychedelic and cannabis industries.
- Potential for strategic partnerships and collaborations to accelerate research, market penetration, and capital access.
What Threats Does NUMIF Face?
- Adverse regulatory changes or setbacks in the legalization of psychedelic substances.
- Intense competition from other emerging psychedelic therapy companies and established pharmaceutical players.
- Challenges in securing adequate funding to support ongoing operations, research, and expansion initiatives.
- Negative public perception or safety concerns related to psychedelic treatments impacting market adoption.
What Are NUMIF's Competitive Advantages?
- **Specialized Expertise and Early Mover Advantage:** Numinus has established itself in the nascent and highly specialized field of psychedelic-assisted psychotherapy and related lab services, building expertise ahead of broader market adoption.
- **Integrated Business Model:** The combination of Numinus Health (clinical services) and Salvation Botanicals (lab and R&D) creates a synergistic ecosystem, allowing for in-house research, protocol development, and direct application, which can enhance efficiency and quality control.
- **Regulatory Navigation and Compliance:** Operating in a complex and evolving regulatory environment for controlled substances, Numinus has developed processes and infrastructure to navigate compliance, which can be a barrier to entry for new competitors.
- **Practitioner Training and Network:** By offering training programs, Numinus is not only building its own internal capacity but also fostering a network of trained professionals, which can support future growth and referrals within the industry.
What Does NUMIF Do?
Numinus Wellness Inc. is a Canadian healthcare company headquartered in Vancouver, dedicated to advancing and delivering psychedelic-assisted psychotherapy with the ambitious goal of transforming the mental healthcare landscape. The company's operational framework is strategically divided into two distinct yet complementary divisions: Salvation Botanicals and Numinus Health. Salvation Botanicals serves as the scientific backbone, offering comprehensive laboratory services specifically tailored to psychedelics. These services encompass critical areas such as cultivation, rigorous analytical testing, product research and development, and various essential ancillary supports for the emerging psychedelic industry. Furthermore, this division extends its expertise to the broader botanical market by providing both full-suite and bespoke testing solutions for cannabis products, ensuring quality and compliance. Concurrently, Numinus Health represents the patient-facing arm of the company, focusing on fostering healing, connection, and personal growth through a diverse array of supportive therapies and advanced technological applications. This division is acutely focused on addressing prevalent mental health challenges and substance abuse disorders. Its service offerings are extensive, including psychotherapy, personalized counselling, neurofeedback, physiotherapy, and a spectrum of other therapeutic modalities designed to promote holistic well-being. Beyond direct patient care, Numinus Health plays a crucial role in professional development by equipping practitioners with vital training, state-of-the-art facilities, and essential operational resources, thereby building capacity within the psychedelic therapy ecosystem. The company's integrated approach, combining scientific research and development with direct clinical application and professional training, positions Numinus Wellness Inc. as a multifaceted player in the evolving field of mental health innovation.
What Products and Services Does NUMIF Offer?
- Provides psychedelic-assisted psychotherapy through its Numinus Health clinics.
- Offers a range of supportive mental health therapies including counselling, neurofeedback, and physiotherapy.
- Conducts comprehensive laboratory services for psychedelics, covering cultivation, analytical testing, and R&D.
- Provides full-suite and bespoke testing for cannabis products.
- Develops and refines therapeutic protocols for mental health and substance abuse.
- Trains practitioners in psychedelic-assisted therapy and other therapeutic modalities.
- Focuses on promoting healing, connection, and personal growth for individuals.
- Operates its headquarters and primary facilities in Vancouver, Canada.
How Does NUMIF Make Money?
- Generates revenue from direct patient services through Numinus Health clinics, offering psychotherapy and other therapeutic modalities.
- Earns income from laboratory services provided by Salvation Botanicals, including analytical testing, cultivation support, and R&D for psychedelics.
- Receives revenue from bespoke and full-suite testing services for cannabis products.
- Monetizes practitioner training programs, equipping mental health professionals with skills in psychedelic-assisted therapy.
- Potentially earns from intellectual property or licensing of proprietary therapeutic protocols developed through its research efforts.
What Industry Does NUMIF Operate In?
Numinus Wellness Inc. is strategically positioned within the burgeoning medical care facilities industry, specifically at the forefront of psychedelic-assisted psychotherapy. This sector is experiencing significant growth driven by increasing awareness of mental health crises and a demand for innovative treatment modalities beyond traditional pharmaceuticals. The broader mental health market is substantial, with global spending on mental health services projected to continue rising. Numinus operates in a competitive landscape that includes other companies developing psychedelic therapies, traditional mental health providers, and research institutions. Its dual model, combining Numinus Health clinics with Salvation Botanicals' lab services, offers a differentiated approach. The industry is characterized by evolving regulatory frameworks, ongoing clinical research, and a need for specialized infrastructure and trained practitioners. Numinus aims to carve out a significant niche by integrating scientific rigor with clinical application, addressing both the therapeutic and research demands of this nascent but rapidly expanding field.
Who Are NUMIF's Key Customers?
- Individuals seeking treatment for mental health conditions such as depression, anxiety, and PTSD.
- Patients struggling with substance abuse disorders looking for alternative therapeutic approaches.
- Mental health practitioners and healthcare professionals seeking specialized training in psychedelic-assisted therapy.
- Companies within the psychedelic industry requiring laboratory services for cultivation, testing, and R&D.
- Cannabis producers and distributors needing analytical testing and quality assurance for their products.
FY2026 estForward Outlook
Wall Street analysts project Numinus Wellness Inc. revenue of about $34.5M for fiscal 2026, with EPS near $0.01.
NUMIF Valuation & Market Position
With a $12.18M market cap, Numinus Wellness Inc. sits in the micro-cap segment of the market. Relative to its peer group, NUMIF's quantitative score of 38/100 is below the peer average of 60/100.
Key Financial Metrics
Its free cash flow yield is -20.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -67.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Numinus Wellness Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Numinus Wellness Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Michael Tan. NUMIF has traded publicly since 2021.
NUMIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Numinus's recent strategic partnerships signal potential expansion and market penetration, suggesting a positive outlook for future revenue streams. Community sentiment indicates growing optimism regarding the company's long-term vision and commitment to research and development. Insider activity, such as stock purchases, could reflect confidence in the company's growth trajectory. The increasing acceptance of psychedelic-assisted therapies may positively impact Numinus's market position and investor confidence.
Bear Case
- Recent market volatility has created uncertainty around emerging sectors like psychedelic wellness, potentially impacting Numinus's stock performance. Some community members express concerns about the regulatory landscape and the potential delays in approvals for psychedelic therapies. Increased competition in the wellness space could challenge Numinus's ability to maintain market share and attract new customers. Negative media coverage or public perception regarding the safety or efficacy of psychedelic treatments could negatively impact investor sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NUMIF Latest News
No recent news available for NUMIF.
NUMIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NUMIF.
Price Targets
Wall Street price target analysis for NUMIF.
NUMIF MoonshotScore
What does this score mean?
The MoonshotScore rates NUMIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Tan
Chief Executive Officer
Michael Tan serves as the Chief Executive Officer of Numinus Wellness Inc., leading the company's strategic direction and operational execution. While specific details regarding his prior career history, educational background, or previous roles before joining Numinus are not provided in the source data, his leadership is central to managing the company's 200 employees and navigating its dual business model in psychedelic-assisted therapy and laboratory services. His role involves overseeing both the Numinus Health clinical division and the Salvation Botanicals research and testing arm, driving the company's mission to reshape mental healthcare.
Track Record: Under Michael Tan's leadership, Numinus Wellness Inc. has continued to develop its integrated approach to mental healthcare, combining clinical services with scientific research. He oversees the management of 200 employees, guiding the company through the complexities of an emerging industry. Key strategic decisions under his tenure include the ongoing development of psychedelic-assisted psychotherapy protocols and the expansion of laboratory services for both psychedelics and cannabis, positioning Numinus as a significant player in this innovative sector.
NUMIF OTC Market Information
Numinus Wellness Inc. trades on the OTC market under the "OTC Other" tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to be listed on those tiers. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing standards including minimum share price, market capitalization, and regular SEC filings, OTC Other companies have significantly less oversight. This often means they provide limited public information, making it harder for investors to conduct thorough due diligence. The "OTC Other" designation implies a higher degree of risk due to less transparency and regulatory scrutiny compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure due to "Unknown" disclosure status, hindering comprehensive investor analysis.
- Lower liquidity and wider bid-ask spreads on the OTC Other market, leading to potential difficulty in trading shares.
- Increased price volatility and susceptibility to market manipulation due to less regulatory oversight.
- Challenges in raising capital and attracting institutional investors compared to exchange-listed companies.
- Potential for delisting or further restrictions if disclosure standards are not met or improved.
- Verify the company's current financial statements and audit reports directly from their investor relations if available.
- Research any recent news, press releases, or corporate filings beyond standard market data.
- Assess the management team's experience and track record through independent sources.
- Understand the specific regulatory environment and risks associated with the psychedelic therapy industry.
- Evaluate the company's capital structure, outstanding shares, and potential dilution risks.
- Investigate any legal or regulatory actions against the company or its management.
- Confirm the legitimacy of the business operations and physical presence.
- Clear and articulated business model focused on psychedelic-assisted psychotherapy and lab services.
- Stated headquarters in Vancouver, Canada, indicating a physical operational base.
- Reported employee count of 200, suggesting a tangible operational scale and workforce.
- Identified CEO, Michael Tan, providing clear leadership accountability.
- Operations in a legitimate, albeit emerging, sector of healthcare (Medical - Care Facilities).
What Investors Ask About Numinus Wellness Inc. (NUMIF) — Healthcare
What does Numinus Wellness Inc. do?
Numinus Wellness Inc. operates in the innovative field of mental healthcare, specializing in psychedelic-assisted psychotherapy and related scientific services. The company's operations are bifurcated into two core divisions: Numinus Health and Salvation Botanicals. Numinus Health focuses on direct patient care, offering a range of supportive therapies such as psychotherapy, counselling, neurofeedback, and physiotherapy, specifically targeting mental health challenges and substance abuse. Concurrently, Salvation Botanicals provides comprehensive laboratory services for psychedelics, including cultivation, analytical testing, and product research and development. This division also extends its expertise to the cannabis industry with full-suite and bespoke testing. The company's integrated model aims to advance and deliver cutting-edge mental health solutions from its Vancouver, Canada headquarters.
How does Numinus Wellness Inc. navigate the evolving regulatory landscape for psychedelics?
Numinus Wellness Inc. operates within a highly dynamic and complex regulatory environment, given its focus on psychedelic-assisted therapies. The company navigates this landscape by adhering to existing regulations in jurisdictions where psychedelic use is permitted for research or therapeutic purposes, such as Canada. Its strategy involves closely monitoring legislative developments and actively participating in the scientific and medical discourse surrounding the legalization and integration of psychedelics into mainstream healthcare. By developing robust clinical protocols and maintaining stringent laboratory standards through Salvation Botanicals, Numinus aims to demonstrate the safety and efficacy required for broader regulatory acceptance. The company's ability to adapt to and influence these evolving frameworks is critical to its operational expansion and market penetration.
What are the financial implications of Numinus Wellness Inc.'s current profitability and market position?
Numinus Wellness Inc.'s current financial profile, marked by a profit margin of -297.9% and a market capitalization of $12.18M, indicates that it is an early-stage company heavily investing in growth and R&D within a nascent industry. The negative profit margin suggests that the company is not yet profitable, likely due to significant operational expenses, research costs, and expansion initiatives. While the gross margin of 41.5% shows some efficiency in its service delivery, the overall unprofitability implies a reliance on external funding to sustain operations and achieve its strategic objectives. Its small market cap and OTC Other listing further highlight its emerging status and the inherent risks associated with companies in highly speculative, yet potentially transformative, sectors.
What are the key factors to evaluate for NUMIF?
Numinus Wellness Inc. (NUMIF) holds an AI score of 38/100 (low). Not financial advice.
How frequently does NUMIF data refresh on this page?
NUMIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NUMIF's recent stock price performance?
Numinus Wellness Inc. (NUMIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual business model integrating clinical services (Numinus Health) with laboratory and R&D capabilities (Salvation Botanicals). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NUMIF overvalued or undervalued right now?
Valuing Numinus Wellness Inc. (NUMIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NUMIF?
Before investing in Numinus Wellness Inc. (NUMIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details are limited to what was provided in the source data.
- OTC disclosure status is explicitly stated as 'Unknown' in the source, impacting the depth of analysis on financial transparency.
- Competitors list is empty as no FMP PEER TICKERS were provided in the source data as per content quality rule 3.